AFM
AVBP icon

Anson Funds Management’s ArriVent BioPharma AVBP Stock Holding History

Anson Funds Management’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-35,366
Closed -$712K – 185
2025
Q4 		$712K Sell
35,366
-64,521
-65% -$1.34M 0.07% 102
2025
Q3 		$1.84M Buy
+99,887
New +$1.96M 0.17% 73

Other funds holding AVBP

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Anson Funds Management's AVBP Position: Q1 2026 in Review

Anson Funds Management sold out of ArriVent BioPharma (AVBP) in Q1 2026, closing a stake of 35,366 shares — an estimated $712K sold.

Anson Funds Management first reported a position in AVBP in Q3 2025 and held it in 2 quarters. The position peaked at $1.84M in Q3 2025. 139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

  • Anson Funds Management reported no remaining ArriVent BioPharma position as of Q1 2026 after selling out during the quarter.
  • Anson Funds Management sold 35,366 ArriVent BioPharma shares in Q1 2026, an estimated $712K.
  • Anson Funds Management first reported a position in ArriVent BioPharma in Q3 2025 and held it in 2 quarters.
  • Anson Funds Management's ArriVent BioPharma position peaked at $1.84M in Q3 2025.
  • 139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on Anson Funds Management's 13F filing for Q1 2026, filed 14 May 2026.